A group of international and multidisciplinary clinical experts and Patient Advocacy Group representatives conducted a survey to investigate screening, therapeutic strategies and patient journeys of hepatocellular cancer (HCC) across the Asia Pacific region. These findings were presented at the poster tour at the opening ceremony of ILCA.

As liver cancer is the leading cause of cancer deaths in several Asian countries, these data can provide insight into the national approach to HCC management for each country, potential areas for improvement, and what to prioritise to shape national policies to improve outcomes for patients.

Clinical Takeaways

  • The awareness of risk factors related to HCC should be increased among both primary care providers and the general Asian population
  • Healthcare practitioners should monitor and manage treatment side effects, maintain a strong communication with patients and deploy trained nurses or case managers in the healthcare team to enhance patient education and support throughout the HCC patient journey
  • There is a need to improve patient access to HCC treatment options known to extend survival rates, such as atezolizumab + bevacizumab

 

Authors

Prof. Rosmawati Mohamed*1, Wendy Wang*2, Tawesak Tanwandee3, Irsan Hasan4, Phuong Pham Cam5, Young-Suk Lim6, Sheng-Nan Lu7, Munisamy Murallitharan8, Huong Tran Thi Thanh9, Evy Ratnawati10, Wattana Sukeepaisarnjaroen11, Mahir Karababa12, Prof. Chee-Kiat Tan13

 

1University of Malaya, Kuala Lumpur, Malaysia; 2Liver Disease Prevention and Treatment Research Foundation, Taiwan; 3Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 4Faculty of Medicine, University Indonesia/Ciptomangunkusumo Hospital, Indonesia; 5Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, and Department of Nuclear Medicine, Ha Noi Medical University, Hanoi, Vietnam; 6Department of Internal Medicine and Department of Gastroenterology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea; 7Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan; 8National Cancer Society of Malaysia, Jalan Raja Muda Abdul Aziz, Wilayah Persekutuan Kuala Lumpur, Malaysia; 9National Cancer Institute, Hanoi, and Vietnam and Hanoi Medical University, Hanoi, Vietnam; 10Indonesian Cancer Information and Support Center (CISC), Indonesia; 11Faculty of Medicine, Khon Kaen University, Khon Kaen, Changwat Khon Kaen, Thailand; 12COR2ED, Basel, Switzerland; 13Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore

Programme summary
Share this programme
This educational programme is supported by an Independent Educational Grant from Roche.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Roche.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Understanding rare non-small cell lung cancer (NSCLC) alterations

Insights and support for patients

Experts
Dr Joshua Sabari, Debra Montague
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim
animated-video Animated Video
Oncology 
ADCs in HR+/HER2- metastatic breast cancer

Optimising treatment strategies and AE management

Experts
Dr Barbara Pistilli
Endorsed by
GRASP
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
podcast Podcast

Episode

2

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2

Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer

Experts
Dr Eric Singhi, Dr Isabel Preeshagul, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.